VVUS:
Patent news out...
MMK
VVUS - Patent News
Wednesday March 24, 8:28 am Eastern Time
Company Press Release
New Erectile Dysfunction Treatment Patent Granted to
VIVUS
MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 24, 1999--VIVUS, Inc.
(Nasdaq:VVUS - news) has been issued patent No. 5,886,039 for the ''Method and
Composition for Treating Erectile Dysfunction'' by the U.S. Patent Office. This patent
provides VIVUS with broad patent
protection for the commercialization of ALIBRA(tm), VIVUS' second-generation
transurethral treatment for male erectile
dysfunction (ED).
ALIBRA is the first transurethral two-drug combination therapy for the treatment of ED.
The two drugs, alprostadil and
prazosin, work by distinct and complementary mechanisms to initiate and maintain
smooth muscle relaxation, the key
physiological event required to achieve penile erection. Additional benefits of ALIBRA
include a redesigned applicator and a
single-strength dosage formulation. Because of these attributes, ALIBRA may become a
welcome new prescribing option for
primary care physicians and ED specialists. ALIBRA is currently in Phase III clinical
trials and VIVUS plans to submit a New
Drug Application for ALIBRA to the FDA during the fourth quarter of 1999.
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic
systems for the treatment of erectile
dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy
for erectile dysfunction known as the
transurethral system for erection. This therapy consists of a proprietary, non-invasive
drug delivery system that delivers
pharmacologic agents via the urethra.
Note to editors and investors: Additional written materials, recent releases and
Company information are available through a
variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS
Fax-On-Demand Service
(1-888-329-5719). |
